scholarly article | Q13442814 |
P50 | author | Yuqing Zhang | Q43157198 |
P2093 | author name string | Hyon K Choi | |
Na Lu | |||
Sharan K Rai | |||
April M Jorge | |||
P2860 | cites work | Current and emerging treatment options in the management of lupus | Q26741266 |
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
Treatment of lupus nephritis: current paradigms and emerging strategies | Q39138845 | ||
Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. | Q40126330 | ||
Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria | Q40672396 | ||
Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis | Q40817900 | ||
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study | Q41418810 | ||
The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
Additive Interaction in Survival Analysis | Q57167120 | ||
Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates | Q64111108 | ||
Mortality studies in SLE: how far can we improve survival of patients with SLE | Q80533656 | ||
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus | Q27021623 | ||
From patient care to research: a validation study examining the factors contributing to data quality in a primary care electronic medical record database | Q30887394 | ||
Life expectancy of different ethnic groups using death records linked to population census data for 4.62 million people in Scotland | Q31118445 | ||
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
Adaptation and validation of the Charlson Index for Read/OXMIS coded databases | Q33522043 | ||
Validation and validity of diagnoses in the General Practice Research Database: a systematic review | Q33588222 | ||
The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study | Q33822203 | ||
Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. | Q34481954 | ||
Selection bias in rheumatic disease research | Q34662693 | ||
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades | Q35551526 | ||
Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States | Q35567251 | ||
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus | Q35879759 | ||
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis | Q36014587 | ||
Malignancies in systemic lupus erythematosus: a 2015 update | Q36035448 | ||
Inequalities in healthy life expectancy between ethnic groups in England and Wales in 2001. | Q36288487 | ||
The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. | Q36475637 | ||
The frequency and outcome of lupus nephritis: results from an international inception cohort study | Q37082037 | ||
Improved survival in rheumatoid arthritis: a general population-based cohort study | Q37531008 | ||
Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort | Q37684625 | ||
Death rates in England and Wales and the United States: variation with age, sex, and race | Q37705578 | ||
Infections in systemic lupus erythematosus | Q37800299 | ||
Management of pregnancy in systemic lupus erythematosus | Q38036105 | ||
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review | Q38082909 | ||
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy | Q38095862 | ||
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies | Q38149856 | ||
Treatment of severe lupus nephritis: the new horizon. | Q38271125 | ||
Advances in use of immunomodulatory agents--a rheumatology perspective | Q38431512 | ||
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
Mortality in systemic lupus erythematosus | Q38467155 | ||
Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. | Q38764974 | ||
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis | Q38884826 | ||
Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. | Q38931444 | ||
P433 | issue | 2 | |
P921 | main subject | systemic lupus erythematosus | Q1485 |
P304 | page(s) | 337-344 | |
P577 | publication date | 2017-11-07 | |
P1433 | published in | Rheumatology | Q7320492 |
P1476 | title | Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). | |
P478 | volume | 57 |
Q55401570 | Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus. |
Q89927588 | Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study |
Q90391852 | Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016 |
Q89486568 | Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study |
Q92540430 | Epidemiology and outcomes of sepsis among hospitalizations with systemic lupus erythematosus admitted to the ICU: a population-based cohort study |
Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
Q92404993 | Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus |
Q98736004 | The Epidemiology and Outcomes of Mental Disorders in Critically Ill Patients With Systemic Lupus Erythematosus: A Population-Based Study |
Q91803860 | The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts |
Search more.